| Heading: |
Pregnancy: Drugs |
| Question ID: |
1813002 |
| UIN: |
60036 |
| House: |
Commons |
| Date tabled: |
2025-06-16 |
| Asking Member ID: |
1506 |
| Asking Member display name: |
Andrew Gwynne
|
| Asking Member handle: |
GwynneMP
|
| Asking Member Twitter reference: |
@GwynneMP
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of prescribing practices of medicines with known teratogenic properties. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-25 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Prescribers are expected to work with patients to make decisions about their care and treatment as part of shared decision-making, and this should include discussing risks, benefits, and possible consequences of different options. Where applicable, the ri... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |